Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAZ696 200/10 mg bioequivalence and food-effect study in healthy Japanese adults
jRCT2031250102Phase 1Completed
- Sponsor
- Novartis
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sacubitril + valsartan and amlodipine (3 arms), sponsored by Novartis. Primary endpoints: Maximum observed plasma concentration, Area under the concentration-time curve to last quantifiable concentration and 1 more. Started Jun 2025; status: completed.
02
Drugs
sacubitril + valsartanamlodipine
Beyond the preview
Go deeper on jRCT2031250102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250102.